A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer

被引：0
|
作者：
Boukovinas, I. [1 ]
Androulakis, N. [1 ]
Polyzos, A. [1 ]
Vardakis, N. [1 ]
Amarantidis, K. [1 ]
Bozionelou, V. [1 ]
Kouroussis, C. [1 ]
Giassas, S. [1 ]
Christophyllakis, C. [1 ]
Mavroudis, D. [1 ]
机构：
[1] Hellen Oncol Res Grp, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4536
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer
    Underhill, Craig R.
    Goldstein, David
    Gorbunova, Vera A.
    Biakhov, Mikhail Y.
    Bazin, Igor S.
    Melemed, Allen
    Hossain, Anwar
    Granov, Dmitry A.
    ANNALS OF ONCOLOGY, 2006, 17 : 118 - 118
  • [42] Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial
    Souglakos, J
    Syrigos, K
    Potamianou, A
    Polyzos, A
    Boukovinas, I
    Androulakis, N
    Kouroussis, C
    Vardakis, N
    Christophilakis, C
    Kotsakis, A
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2004, 15 (08) : 1204 - 1209
  • [43] A phase Ⅱ trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
    YANG Lin
    SONG Yan
    ZHOU Ai-ping
    QIN Qiong
    CHI Yihebali
    HUANG Jing
    WANG Jin-wan
    中华医学杂志（英文版）, 2013, 126 (18) : 3470 - 3474
  • [44] Oxaliplatin and Irinotecan in advanced gastric cancer.: A multicenter phase II trial
    Woell, E.
    Eisterer, W.
    Hilbe, W.
    Kuehr, T.
    Gattringer, K.
    Greil, R.
    Zabernigg, A.
    Baldinger, C.
    Thaler, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 213 - 213
  • [45] Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer
    YAO Yang SUN Yuanjue ZHAO Hui GUO Yuewu LIN Feng CAI Xun TANG Xiaochun TANG Lina and ZHANG Wei Department of Oncology Shanghai Sixth Peoples Hospital of Shanghai Jiaotong University Shanghai China Department of Epidemiology Cancer Research Institute of Shanghai Jiaotong University Shanghai China
    ChineseMedicalJournal, 2006, (21) : 1829 - 1833
  • [46] A Phase II Study of Capecitabine plus Oxaliplatin as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer
    Xiang, Xiao Jun
    Zhang, Ling
    Qiu, Feng
    Yu, Feng
    Zhan, Zheng Yu
    Feng, Miao
    Yan, Jun
    Zhao, Jian Guo
    Xiong, Jian Ping
    CHEMOTHERAPY, 2012, 58 (01) : 1 - 7
  • [47] Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer
    YAO Yang
    中华医学杂志(英文版), 2006, (21) : 1829 - 1833
  • [48] Concurrent irinotecan, oxaliplatin and uft/lv triple therapy as first-line treatment for advanced colorectal cancer (ACRC)
    Sheikh, H. Y.
    Valle, J. W.
    Palmer, K.
    Sjursen, A.
    Wilson, G.
    Swindel, R.
    Saunders, M. P.
    EJC SUPPLEMENTS, 2005, 3 (02): : 189 - 190
  • [49] Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer
    Yao Yang
    Sun Yuan-jue
    Zhao Hui
    Guo Yue-Wu
    Lin Feng
    Cai Xun
    Tang Xiao-chun
    Tang Li-na
    Zhang Wei
    CHINESE MEDICAL JOURNAL, 2006, 119 (21) : 1829 - 1833
  • [50] Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
    Guo, Weijian
    Zhu, Xiaodong
    Huang, Mingzhu
    Wang, Yusheng
    Chen, Zhiyu
    Feng, Wanjing
    He, Yifu
    Zhang, Xiaowei
    Liu, Xin
    Wang, Chenchen
    Zhang, Wen
    Ying, Jieer
    Wu, Jun
    Yang, Lei
    Qin, Yanru
    Zhao, Xiaoying
    Li, Wenhua
    Zhang, Zhe
    Qiu, Lixin
    Wang, XiaoFeng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345